온코닉테라퓨틱스

476060KOSDAQ자연과학 및 공학 연구개발업

67.2 / 100

Reference Date: 2026-07-24

Financial Score28.0 / 40

News Sentiment20.2 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 18.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Onconic Therapeutics focuses on developing innovative drugs for unmet medical needs in gastroesophageal reflux disease and oncology, emphasizing cost-effective small-molecule compounds. Its key product, 'Zastaprazan,' a P-CAB mechanism drug, has completed Phase 3 trials and received approval, while its next-generation oncology candidate 'Nesuparib' is in various clinical trials.

Number of Employees

38people

Average Salary

78.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

32.17Industry Average 43.646.5Point

Lower than industry avg (good)

PBR

7.28Industry Average 2.520.0Point

2.9x industry avg (risky)

ROE

24.65Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

0.06Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2024~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲259.8% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲363.0% (1-year basis)

ROE Trend

4.0 / 4

Detailed News Sentiment

8 totalPositive 7Neutral 1Negative 0Average Sentiment Score 80.6

Neutral
탈모 테마 삼익제약 '上'…코오롱티슈진, 레몬헬스케어 20%대↓[바이오...
삼익제약의 상한가는 해당 섹터 내 긍정적 흐름을 보여주지만, 온코닉테라퓨틱스(476060)에 직접적인 영향은 제한적이다.
Positive
[바이오스냅] 온코닉 "네수파립, 자궁내막암 비임상서 유효성"
온코닉테라퓨틱스의 신약 후보물질 네수파립이 자궁내막암 비임상 시험에서 긍정적인 항암 효과를 보여주며 주가 상승 기대.
Positive
온코닉 ‘자큐보’ 병용처방 늘어난다
온코닉테라퓨틱스의 신약 자큐보가 심혈관계 치료제와의 병용처방 확대를 통해 시장 경쟁력 강화.

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 11,550Won52-week high 26,30052-week low 5,737

1-month return0.0Point

1m -18.66% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral투자판단관련주요경영사항(임상시험결과) (자큐보정(JP1366)(자스타프라잔시트르산염)의 약물상호작용 확인을 위한 제1상 임상시험 결과)2026-07-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-03
Neutral투자판단관련주요경영사항(임상시험계획변경승인) (자큐보정(JP1366)의 미란성 위식도역류질환 치료 후 유지요법에 대한 제3상 임상시험계획승인(변경승인))2026-07-02